Indivior Pharmaceuticals Inc
NASDAQ:INDVDrug Manufacturers - Specialty & Generic
+$0.26 today
- Market cap
- $4.53B
- Beta
- 1.17
- P/E (TTM)
- 19.1
- EPS (TTM)
- $2.00
Volume 3.65M
Average 2.08M
INDV Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Indivior Pharmaceuticals IncNASDAQ: INDV
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $122M rose 577.8% year over year, ahead of the +132.7% change in trailing-twelve-month net income. Sequentially, it rose 37.1% from the prior quarter.
Context
- Net income amounted to 16.9% of revenue in FY2025, up 16.4 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of $516.6M (+146.0%) for the fiscal year ending Dec 2026, a slowdown from the +2900.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $122M+37.1% QoQ
- Last fiscal yearDec 2025
- $210M+2900.0% YoY
- LTMJun 2026
- $356M+132.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +577.8% | +200.9% | -376.8 pp |
| 1 year | +2900.0% | +146.0% | -2754.0 pp |
| 3-year CAGR | — | +43.4% | — |
| 5-year CAGR | +27.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 210M USD
- Year-over-year change
- +2900.0%
- 4-year CAGR
- -0.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 210M | +2900.0% |
| FY2024 | 2024-12-31 | 7M | +105.6% |
| FY2023 | 2023-12-31 | (126M) | -186.4% |
| FY2022 | 2022-12-31 | (44M) | -120.7% |
| FY2021 | 2021-12-31 | 213M | — |
Net Income vs competitors
How INDV compares with its peers on the latest reported figures
- INDV's LTM Jun 2026 net income of $356M is the largest of the 4 companies compared; the peer median is $351K.
- Its year-over-year change of +132.7% is the highest of 4, against a peer median of -100.1%.
- Net income amounts to 26.7% of revenue for INDV, versus a peer median of 9.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
INDVIndivior Pharmaceuticals Inc | LTM Jun 2026 | $356M | +132.7% | — | 26.7% |
| LTM Jun 2026 | $144.33M | -323.8% | — | 17.4% | |
| LTM Mar 2026 | $74.95M | +70.7% | — | 9.4% | |
| LTM Sep 2026 | $351K | -100.1% | — | 0.0% | |
| Peer median (excluding INDV) | $351K | -100.1% | — | 9.4% | |
Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 213M | (44M) | (126M) | 7M | 210M |
| Depreciation & Amortization | 22M | 16M | 15M | 28M | 20M |
| Deferred Income Tax | 0 | 0 | (64M) | 7M | (46M) |
| Stock-Based Compensation | 11M | 16M | 21M | 24M | 26M |
| Change in Working Capital | 173M | 118M | (297M) | (46M) | (257M) |
| Accounts Receivables | (25M) | (21M) | (33M) | (1M) | 3M |
| Inventory | (3M) | (30M) | (6M) | (43M) | 18M |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 201M | 169M | (258M) | (2M) | (278M) |
| Other Non-Cash Items | (66M) | (110M) | 151M | 16M | 20M |
| Operating Cash Flow | 353M | (4M) | (300M) | 36M | (27M) |
| Capital Expenditures | (34M) | (5M) | (53M) | (31M) | (67M) |
| Acquisitions (Net) | 0 | 0 | (129M) | 0 | 0 |
| Purchases of Investments | 0 | (245M) | (45M) | (17M) | (20M) |
| Sales of Investments | 0 | 27M | 129M | 117M | 20M |
| Other Investing Activities | (10M) | 1M | (42M) | (2M) | 0 |
| Investing Cash Flow | (14M) | (222M) | (95M) | 69M | (66M) |
| Debt Repayment | 14M | (3M) | (12M) | 92M | (17M) |
| Common Stock Issued | 1M | (8M) | (19M) | (19M) | (3M) |
| Common Stock Repurchased | (101M) | (90M) | (33M) | (173M) | (11M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8M) | 0 | 0 | (2M) | 1M |
| Financing Cash Flow | (94M) | (101M) | (64M) | (102M) | (30M) |
| Effect of Forex Changes | (1M) | (1M) | 1M | 0 | (1M) |
| Net Change in Cash | 244M | (328M) | (458M) | 3M | (124M) |
| Free Cash Flow | 319M | (9M) | (353M) | 5M | (94M) |
Indivior Pharmaceuticals Inc
NASDAQ:INDV
Intrinsic Alpha fair value
Locked
Current Price
$36.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.